心脏外科中的基因治疗：临床试验、挑战与展望
Gene Therapy in Cardiac Surgery: Clinical Trials, Challenges, and Perspectives.
作者信息
Katz Michael G, Fargnoli Anthony S, Kendle Andrew P, Hajjar Roger J, Bridges Charles R
机构信息
Sanger Heart and Vascular Institute, Charlotte, North Carolina; Mount Sinai School of Medicine, New York, New York.
Sanger Heart and Vascular Institute, Charlotte, North Carolina.
出版信息
Ann Thorac Surg. 2016 Jun;101(6):2407-16. doi: 10.1016/j.athoracsur.2015.12.004. Epub 2016 Jan 20.
The concept of gene therapy was introduced in the 1970s after the development of recombinant DNA technology. Despite the initial great expectations, this field experienced early setbacks. Recent years have seen a revival of clinical programs of gene therapy in different fields of medicine. There are many promising targets for genetic therapy as an adjunct to cardiac surgery. The first positive long-term results were published for adenoviral administration of vascular endothelial growth factor with coronary artery bypass grafting. In this review we analyze the past, present, and future of gene therapy in cardiac surgery. The articles discussed were collected through PubMed and from author experience. The clinical trials referenced were found through the Wiley clinical trial database (http://www.wiley.com/legacy/wileychi/genmed/clinical/) as well as the National Institutes of Health clinical trial database (Clinicaltrials.gov).
20世纪70年代重组DNA技术发展之后，基因治疗的概念被提出。尽管最初人们寄予厚望，但该领域早期却遭遇了挫折。近年来，基因治疗的临床项目在医学的不同领域再度兴起。作为心脏手术的辅助手段，基因治疗有许多有前景的靶点。血管内皮生长因子腺病毒给药联合冠状动脉搭桥术的首个长期阳性结果已发表。在本综述中，我们分析了心脏手术中基因治疗的过去、现在和未来。所讨论的文章通过PubMed以及作者经验收集。所引用的临床试验通过Wiley临床试验数据库（http://www.wiley.com/legacy/wileychi/genmed/clinical/）以及美国国立卫生研究院临床试验数据库（Clinicaltrials.gov）找到。
Zotero 插件